Prospective clinical study on the safety and efficacy of rapamycin in the treatment of unresectable or postoperative residual benign peripheral neuroblastic tumors

Prospective clinical study on the safety and efficacy of rapamycin in the treatment of unresectable or postoperative residual benign peripheral neuroblastic tumors - Prospective clinical study of rapamycin in the treatment of GNBi and GN tumor residues

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300070701

Enrollment

Unknown

Registered

2023-04-20

Start date

2023-04-10

Completion date

Unknown

Last updated

2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign peripheral neuroblastic tumors (including GNBi and GN)

Interventions

Experimental group:rapamycin

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1:From January 1,2007 to January 1,2028, he was admitted to the Department of Tumor Surgery, Beijing Children's Hospital Affiliated to Capital Medical University. He was pathologically confirmed to be a benign peripheral neuroblastic tumor [including gangliocytic neuroblastoma hybrid (GNBi) and gangliocytic neuroma (GN)], which could not be resected or remained after surgery 2:Under the age of 18 3:The patient's parents signed the informed consent voluntarily 4:Receiving standardized treatment in the Surgery Department of Cancer of Beijing Children's Hospital

Exclusion criteria

Exclusion criteria: 1:Patients with severe complications who were unable to participate in the study 2:Liver or lung transplant patients 3:Autoimmune disorder 4:Allergic to rapamycin and its derivatives and the ingredients of this product 5:Poor adherence to treatment or clinical studies 6:Discontinuation of treatment or follow-up if a non-medical event occurs during treatment

Design outcomes

Primary

Measure	Time frame
safety;efficiency;	—

Secondary

Measure	Time frame
To explore the blood concentration range of rapamycin in the treatment of GNBi/GN;	—

Countries

China

Contacts

Public ContactHuanmin Wang

Beijing Children’s Hospital, Capital Medical University

wanghuanmin@bch.com.cn+86 10 59616413

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026